Skip to main content

Advertisement

SpringerLink
Log in

Chemotherapy-Resistant Metastatic Breast Cancer

  • Breast Cancer (CI Falkson, Section Editor)
  • Published:
Current Treatment Options in Oncology Aims and scope Submit manuscript

Opinion statement

Remaining the most common cancer in women through the 21st century, breast cancer and the development of treatment strategies continue to highlight advances made in our understanding of the pathogenesis of cancer development and resistance to therapies. Despite significant progress in the treatment of breast cancer, resistance to chemotherapeutic agents remains a consistent obstacle in terms of treatment success. Anthracyclines, first used over 30 years ago, and the more recent addition of taxanes to the treatment armamentarium are integral components for both newly diagnosed and recurrent breast cancer. Unfortunately, along with other constituents of combination chemotherapy for metastatic breast cancer, these agents ultimately become ineffective in controlling disease. With the emergence of a resistant phenotype, tumors are deemed to be drug resistant - frequently multidrug resistant (MDR). A number of processes have been identified that can underlie clinical drug resistance; observations stemming largely from in vitro laboratory-based studies in human cancer cell lines. Recognized mechanisms of resistance include altered expression of the adenosine triphosphate-binding cassette (ABC) superfamily of transporters, alteration in DNA repair pathways, mutations in cellular targets, resistance to initiation of the apoptotic pathway and the development of constitutively activated signaling pathways. As our understanding of mechanisms of resistance expands, the ability to select specific drugs or drug combinations specific to the phenotype of the cancer will become more specific. Illustrative of these advancements are the reported benefits from the use of newer microtubule-targeting agents in triple negative breast cancer, such as eribulin and ixabepilone; drugs which may be less susceptible to common pathways of drug resistance. Likewise, the combination usage of agents which intersect in receptor crosstalk, such as between the estrogen receptor and the mammalian target of rapamycin (mTOR), have demonstrated synergy in antitumor effects. The recent report of exemestane used in combination with everolimus, have shown great promise in this regard. For patients with HER2 positive disease, a combination approach with trastuzumab and investigational agents such as pertuzumab appear to result in a more complete blockage of HER2 signaling, and improved progression free survival. Thus, as our understanding of the interconnectedness of signaling pathways in breast cancer improves, the ability to rationally design appropriate chemotherapy regimens and delay emerging resistance will improve.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Hall MD, Handley MD, Gottesman MM. Is resistance useless? Multidrug resistance and collateral sensitivity. Trend Pharmacol Sci. 2009;30(10):546–56.

    Article  CAS  Google Scholar 

  2. Szakacs G, Paterson JK, Ludwig JA, Booth-Genthe C, Gottesman MM. Targeting multidrug resistance in cancer. Nat Rev Drug Discov. 2006;5(3):219–34.

    Article  PubMed  CAS  Google Scholar 

  3. Twentyman PR. Cyclosporins as drug resistance modifiers. Biochem Pharmacol. 1992;43:109–17.

    Article  PubMed  CAS  Google Scholar 

  4. Cripe LD, Uno H, Paietta EM, et al. Zosuquidar, a novel modulator of P-glycoprotein, does not improve the outcome of older patients with newly diagnosed acute myeloid leukemia: a randomized, placebo-controlled trial of the Eastern Cooperative Oncology Group 3999. Blood. 2010;116:4077–85.

    Article  PubMed  CAS  Google Scholar 

  5. Ruff P, Vorobiof DA, et al. A randomized, placebo-controlled, double-blind phase 2 study of docetaxel compared to docetaxel plus zosuquidar (LY335979) in women with metastatic or locally recurrent breast cancer who have received one prior chemotherapy regimen. Canc Chemother Pharmacol. 2009;64(4):763–8.

    Article  CAS  Google Scholar 

  6. Ferlini C, Raspaglio G, Cicchillitti L, et al. Looking at drug resistance mechanisms for microtubule interacting drugs: Does TUBB3 work? Curr Cancer Drug Targets. 2007;7:704–12.

    Article  PubMed  CAS  Google Scholar 

  7. Seve PS, Dumontet C. Is class III β-tubulin a predictive factor in patients receiving tubulin-binding agents? Lancet Oncol. 2009;9:168–75.

    Article  Google Scholar 

  8. Lee FY, Smykla R, Johnston K, et al. Preclinical efficacy spectrum and pharmacokinetics of ixabepilone. Canc Chemother Pharmacol. 2009;63:201–12.

    Article  CAS  Google Scholar 

  9. Denduuluri N, Swain S. Ixabepilone: clinical role in metastatic breast cancer. Clin Breast Cancer. 2011;3:139–45.

    Article  Google Scholar 

  10. Sparano JA, Vrdoljak E, Rixe O, Xu B, et al. Randomized phase III trial of ixabepilone plus capecitabine versus capecitabine in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. JCO. 2010;28:3256–63.

    Article  CAS  Google Scholar 

  11. Fornier M, Fumoleau P. The paradox of triple negative breast cancer: novel approaches to treatment. The Breast Journal 2011; doi: 10.1111/j.1524-4741.2011.01175.x. Provides a succinct overview of approaches to a subgroup of breast cancer that epitomizes the improvements made in defining breast cancer at a molecular level.

  12. Jimeno A. Eribulin: rediscovering tubulin as an anticancer target. Clin Cancer Res. 2009;15:3903–5.

    Article  PubMed  CAS  Google Scholar 

  13. Jordan MA, Kamath K, Manna T, et al. The primary antimitotic mechanism of action of the synthetic halichondrins E7389 is suppression of microtubule growth. Mol Cancer Ther. 2005;4:1086–95.

    Article  PubMed  CAS  Google Scholar 

  14. Cortes, et al. Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study Lancet. 2011;377:914–23.

    Article  PubMed  CAS  Google Scholar 

  15. Ribeiro JT, Macedo LT, Curigliano G, et al. Cytotoxic drugs for patients with breast cancer in the era of targeted treatment: back to the future? Ann Oncol. 2011. doi:10.1093/annonc/mdr382.

  16. Anton Aparicio LM, Pulido EG, Gallego GA. Vinflunine: a new vision that may translate into antiangiogenic and antimetastatic activity. Anticancer Drugs 2012 Jan23(1):1–11.

    Google Scholar 

  17. Capone, et al. Vinflunine: a new active drug for second-line treatment of advanced breast cancer. Results of a phase II and pharmacokinetic study in patients progressing after first-line anthracycline/taxane-based chemotherapy. Br J Cancer. 2006;95:1161–6.

    Article  Google Scholar 

  18. Fumoleau P, Cortes-Funes H, Taleb AB, Chan S, et al. Phase 2 study of single-agent IV vinflunine as third-line treatment of metastatic breast cancer after failure of anthracycline/taxane-based chemotherapy. Am J Clin Oncol. 2009;32(4):375–80.

    Article  PubMed  CAS  Google Scholar 

  19. Campone M, Isambert N, Bourbouloux E, et al. A phase I study of vinflunine in combination with capecitabine in patients with metastatic breast cancer previously treated with anthracyclines and taxanes. Canc Chemother Pharmacol. 2011. doi:10.1007/s00280-011-1767-9.

  20. Venkitaraman AR. Linking the cellular functions of BRCA genes to cancer pathogenesis and treatment. Annu Rev Pathol. 2009;4:461–87.

    Article  PubMed  CAS  Google Scholar 

  21. Rios J, Puhalla S. PARP inhibitors in breast cancer: BRCA and beyond. Oncology. 2011;25(11):1014–25.

    PubMed  Google Scholar 

  22. Rakha EA, Reis-Filho JS, Ellis IO. Basal-like breast cancer: a critical review. J Clin Oncol. 2008;26(15):2568–81.

    Article  PubMed  Google Scholar 

  23. Tutt A, Robson M, Garber JE, et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: A proof-of-concept trial. Lancet. 2010;376:235–44.

    Article  PubMed  CAS  Google Scholar 

  24. Audeh MW, Carmichael J, Penson RT, et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: A proof-of-concept trial. Lancet. 2010;376:245–51.

    Article  PubMed  CAS  Google Scholar 

  25. Isakoff SJ, Overmoyer B, Tung NM, et al. A phase II trial of the PARP inhibitor veliparib (ABT888) and temozolomide for metastatic breast cancer. J Clin Oncol. 2010;28(suppl):118s. abstr 1019.

    Google Scholar 

  26. Sandhu SK, Wenham RM, Wilding G, et al. First-in-human trial of a poly(ADP-ribose) polymerase (PARP) inhibitor MK-4827 in advanced cancer patients (pts) with antitumor activity in BRCA-deficient and sporadic ovarian cancers. J Clin Oncol. 2010;28(suppl):233s. abstr 3001.

    Google Scholar 

  27. O'Shaughnessy J. A randomized phase III study of iniparib (BSI-201) in combination with gemcitabine/carboplatin in metastatic triple-negative breast cancer. J Clin Oncol. 2011;29(suppl):81s. abstr 1007.

    Google Scholar 

  28. Roderiguez AA, Makris A, Wu MF, et al. DNA repair signature is associated with anthracycline response in triple negative breast cancer patients. Breast Cancer Res Treat. 2010;123:189–96.

    Article  Google Scholar 

  29. Arteaga CL, Sliwkowski MX, Osborne CK, et al. Treatment of HER2-positive breast cancer: current status and future perspectives. Nat Rev Clin Oncol. 2011;9(1):16–32.

    Article  PubMed  Google Scholar 

  30. Lee-Hoeflich ST, et al. A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy. Cancer Res. 2008;68:5878–87.

    Article  PubMed  CAS  Google Scholar 

  31. Campbell MR, Amin D, Moasser MM. Her3 comes of age: new insights into its functions and role in signaling, tumor biology, and cancer therapy. Clin Cancer Res. 2010;16:1209–18.

    Article  Google Scholar 

  32. Bedard PL, de Azambuja E, Cardoso F. Beyond trastuzumab: overcoming resistance to targeted HER-2 therapy in breast cancer. Curr Cancer Drug Targets. 2009;9(2):148–62.

    Article  PubMed  CAS  Google Scholar 

  33. De P, Leyland-Jones B. Whither HER2-related therapeutics? J Clin Oncol. 2010;28(7):1091–6.

    Article  PubMed  CAS  Google Scholar 

  34. Agus, DB, Gordon MS, Taylor C, et al. Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer. JCO2005:2534–2543.

  35. Baselga J, Gelmon KA, Verma S, et al. Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy. JCO 2010:1138–1144.

  36. LoRusso PM, Weiss D, Guardino E, Girish S, Silwkowski MX. Trastuzumab emtansine: a unique antibody-drug conjugate in development for human epidermal growth factor receptor 2-positive cancer. Clin Cancer Res. 2011;17(20):6437–47.

    Article  PubMed  CAS  Google Scholar 

  37. Schoeberl B, Faber AC, Li D, et al. An ErbB3 antibody, MM-121, is active in cancer with ligand-dependent activation. Cancer Res. 2010;70(6):2485–94.

    Article  PubMed  CAS  Google Scholar 

  38. Arpino G, Weichmann L, Osborne CK, et al. Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family. Endocr Rev. 2008;29:217–33.

    Article  PubMed  CAS  Google Scholar 

  39. Johnston S, Pippen Jr J, Pivot X, et al. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J Clin Oncol. 2010;27:5538–46.

    Article  Google Scholar 

  40. Ghayad SE, Vendrell JA, Larbi SB, et al. Endocrine resistance associated with activated ErbB system in breast cancer cells is reversed by inhibiting MAPK or PI3K/Akt signaling pathways. Int J Cancer. 2010;126(2):545–62.

    Article  PubMed  CAS  Google Scholar 

  41. Pandolfi PP. Breast cancer: Loss of PTEN predicts resistance to treatment. N Engl J Med. 2004;351:2337–8.

    Article  PubMed  CAS  Google Scholar 

  42. Morrow PK, Wulf GM, Ensor J, et al. Phase I/II study of trastuzumab in combination with everolimus (RAD001) in patients with HER2-overexpressing metastatic breast cancer who progressed on trastuzumab-based therapy. JCO. 2011;29:3126–32.

    Article  CAS  Google Scholar 

  43. Miller TW, Balko JM, Arteaga CL. Phosphatidylinositol 3-kinase and antiestrogen resistance in breast cancer. J Clin Oncol. 2011;29:4452–61.

    Article  PubMed  CAS  Google Scholar 

  44. Baselga j, Campone M, Sahmoud T, et al. Everolimus in combination with exemestane for postmenopausal women with advanced breast cancer who are refractory to letrozole or anastrozole: Reports of the BOLERO-2 phase III trial. 2011 European Multidisciplinary Cancer Congress. Abstact 9LBA, 2011.

  45. Baselga J, Campone M, Piccart M et al. Everolimus in postmenopausal hormone-receptor positive advanced breast cancer. N Engl J Med 2011 Dec (Epub ahead of print). Represents an early success story in the use of combining agents targeting intersecting pathways that are drivers for breast cancer proliferation.

  46. Alvarez RH, Guarneri V, et al. Bevacizumab treatment for advanced breast cancer. Oncologist 2011 Dec 6 Epub ahead of print.

  47. Valachis A, Polyzos NP, Patsopoulos NA, et al. Bevacizumab in metastatic breast cancer: a meta-analysis of randomized controlled trials. Breast Cancer Res Treat. 2010;122(1):1–7.

    Article  PubMed  CAS  Google Scholar 

  48. Miller KD, O’Neill A, Perez EA, Seidman AD, Sledge GW. A phase II pilot trial incorporating bevacizumab into dose-dense doxorubicin and cyclophosphamide followed by paclitaxel in patients with lymph node positive breast cancer: a trial coordinated by the Eastern Cooperative Oncology Group. Ann Oncol 2011 Aug 4 (Epub ahead of print).

  49. Forero-Torres A, Salhe MN, Galleshaw, Jones CF, Shah JJ, Percent IJ, Nabell LM, Carpenter JC, et al. Pilot trial of preoperative (neoadjuvant) letrozole in combination with bevacizumab in postmenopausal women with newly diagnosed estrogen receptor-or progesterone receptor-positive breast cancer. Clin Breast Cancer. 2010;10(4):275–80.

    Article  PubMed  CAS  Google Scholar 

  50. Yarkley DA, Burris HA, Clark BL, Shipley D, et al. Hormonal therapy plus bevacizumab in postmenopausal patients who have hormone recepor-positive metastatic breast cancer: a phase II trial of the Sarah Cannon Oncology Research Consortium. Clin Breast Cancer. 2011;11(3):146–52.

    Article  Google Scholar 

  51. Crown J, et al. (2010) Phase III trial of sunitinib (SU) in combination with capecitabine (C) versus C in previously treated advanced breast cancer (ABC) J Clin Oncol 28(suppl; abstr LBA1011):18 s.

    Google Scholar 

  52. Kerbel RS. Reappraising antiangiogenic therapy for breast cancer.Breast 2011;Suppl3:S56-60.

  53. Al-Hajj M, Wicha MS, Benito-Hernandez A, et al. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA. 2003;100:3983–8.

    Article  PubMed  CAS  Google Scholar 

  54. Charafe-Jauffret E, Ginestier C, Iovino F, et al. Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature. Cancer Res. 2009;69:1302–13.

    Article  PubMed  CAS  Google Scholar 

  55. Liu S, Wicha MS. Targeting Breast Cancer Stem Cells. J Clin Oncol. 2010;28:4006–12.

    Article  PubMed  CAS  Google Scholar 

  56. Korkaya H, Paulson A, Iovino F, et al. HER2 regulates the mammary stem/progenitor cell population driving tumorigenesis and invasion. Oncogene. 2008;27:6120–30.

    Article  PubMed  CAS  Google Scholar 

  57. Korkaya H, Paulson A, Charafe-Jauffret E, et al. Regulation of mammary stem/progenitor cells by PTEN/Akt/beta-catenin signaling. PLoS Biol. 2009;7:e1000121.

    Article  PubMed  Google Scholar 

  58. Ashkenazi A, Holland P, Eckhardt SG. Ligand-based targeting of apoptosis in cancer: the potential of recombinant human apoptosis ligand 2/tumor necrosis factor-related apoptosis-inducing ligand (rhApo2L/TRAIL). JCO. 2008;26:3621–30.

    Article  CAS  Google Scholar 

  59. Ghobrial IM, Witzig TE, Adjei AA. Targeting apoptosis pathways in cancer therapy. CA Cancer J Clin 2005:178–194.

  60. Londono-Joshi AI, Oliver PG, Li Y, et al. Basal-like breast cancer stem cells are sensitive to anti-DR5 mediated cytotoxicity. Breast Cancer Res 2011 Sept (Epub ahead of print).

  61. Lee JIY, Huerta-GYepez SH, Vega M, et al. The no trail to yes trail in cancer therapy (review). Int J of Oncology. 2007;31:685–91.

    CAS  Google Scholar 

  62. Garimella SV, Rocca A, Lipkowitz S. WEE1 inhibition sensitizes basal breast cancer cells to TRAIL-induced apoptosis. Mol Cancer Res 2011 Dec 20 (Epub ahead of print).

  63. Piggott, L, Omidvar N, Perez SM, et al. Suppression of apotosis inhibitor c-FLIP selectively eliminates breast cancer cell activity in response to the anti-cancer agent, TRAIL. Breast Cancer Res 2011;13(5):

  64. Rahman M, Davis SR, Pumphrey JG, et al. TRAIL induces apoptosis in triple-negative breast cancer cells with a mesenchymal phenotype. Breast Cancer Res Treat. 2009;113:217–30.

    Article  PubMed  Google Scholar 

  65. Forero-Torres A, Shah J, Wood T, Posey J, et al. Phase I trial of weekly tigatuzumab, an agonistic humanized monoclonal antibody targeting death receptor 5 (DR5). Cancer Biother Radiopharm. 2010;1:13–9.

    Article  Google Scholar 

  66. Barginear MF, v Poznak C, Rosen N, et al. The heat shock protein 90 chaperone complex: an evolving therapeutic target. Curr Cancer Drug Targets. 2008;6:522–32.

    Article  Google Scholar 

  67. Modi S, Stopeck A, Linden H, et al. HSP90 inhibition is effective in breast cancer: a phase II trial of tanespimycin (17-AAG) plus trastuzumab in patients with HER2-positive metastatic breast cancer progressing on trastuzumab. Clin Cancer Res. 2011;17(15):5132–9.

    Article  PubMed  CAS  Google Scholar 

Download references

Disclosure

No potential conflicts of interest relevant to this article were reported.

Author information

Authors and Affiliations

  1. 2540 B 1824 6th Avenue South, Birmingham, AL, 35294, USA

    Carrie Marquette MD & Lisle Nabell MD

Authors
  1. Carrie Marquette MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lisle Nabell MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Carrie Marquette MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Marquette, C., Nabell, L. Chemotherapy-Resistant Metastatic Breast Cancer. Curr. Treat. Options in Oncol. 13, 263–275 (2012). https://doi.org/10.1007/s11864-012-0184-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11864-012-0184-6

Keywords

Search

Navigation